• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. med. Stephan Mathas

Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie
Charité - Universitätsmedizin Berlin
Hindenburgdamm 30
12200 Berlin
Tel: +49 30 8445 4468

E-Mail: stephan.mathas(at)charite.de

University Education

  • 1990-1997 Studies of Human Medicine at the Universität Köln
  • 2000 Dissertation at the Universität Köln

Professional Experience (selection)

  • 1997- Resident at the Charité, Department of Hematology, Oncology and Tumor Immunology
  • 1999-2002 Scientific work at the MDC (“Klinisches Ausbildungsprogramm”) in collaboration with Claus Scheidereit
  • 2002- Resident and Principal investigator at the Charité, Hematology, Oncology and Tumor immunology and at the MDC

Most important Awards, Grants or Scientific Achievements

  • 2004 C. G. Schmidt-Medal of the West German Cancer Center
  • 2007 Curt-Meyer-Prize of the Berlin Cancer Society
  • 2010 Artur Pappenheim Award for Hematology and Oncology of the German Society of Hematology and Oncology

Selected References

  • Lamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., …, Dörken, B., Bonifer, C., and Mathas, S. (2010). Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16, 571.
  • Lamprecht, B., Kreher, S., Anagnostopoulos, I., Jöhrens, K., Monteleone, G., Jundt, F.,…, Dörken, B., and Mathas, S. (2008). Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112, 3339.
  • Mathas, S.*, Janz, M.*, Hummel, F., Hummel, M., Wollert-Wulf, B.,…, Jundt, F.,…,  Dörken, B. (2006). Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of the neoplastic B cells in Hodgkin lymphoma. Nat Immunol 7, 207. *Authors contributed equally.